Trial Profile
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Calcium; Vitamin D
- Indications Advanced breast cancer; Bone disorders; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms REDUSE
- 20 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2023 Planned End Date changed from 1 Dec 2022 to 31 Dec 2028.
- 09 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 30 Jun 2026.